Literature DB >> 23018145

Linkage between C-reactive protein and triglyceride-rich lipoprotein metabolism.

Nuntakorn Thongtang1, Margaret R Diffenderfer, Esther M M Ooi, Bela F Asztalos, Gregory G Dolnikowski, Stefania Lamon-Fava, Ernst J Schaefer.   

Abstract

OBJECTIVE: Inflammation plays an important role in atherosclerosis. Elevated C-reactive protein (CRP) levels are associated with a greater risk of cardiovascular disease. Our goal was to study CRP metabolism, and to determine its relationship with lipoprotein metabolism using stable isotope methodology. MATERIAL/
METHODS: Eight subjects with combined hyperlipidemia underwent a 15-h primed-constant infusion with deuterated leucine. CRP was purified from the plasma density fraction greater than 1.21g/ml by affinity chromatography. Lipoprotein fractions were separated by sequential ultracentrifugation. Isotope enrichment was determined by gas chromatography/mass spectrometry.
RESULTS: The subjects had mean LDL-C levels of 147.5mg/dl and mean CRP levels of 3.4mg/l. The mean CRP production rate (PR) was 0.050±0.012mg/kg/day and the mean CRP fractional catabolic rate (FCR) was 0.343±0.056 pools/day (residence time 2.92days). CRP pool size (PS) was significantly related to production (r=0.93; p<0.001), but not FCR. CRP PS was also related to body mass index (r=0.79; p=0.02). There was a significant association between CRP FCR and TRL apoB-100 FCR (r=0.74, p=0.04), as well as between CRP PS and TRL apoB-48 FCR (r=-0.90, p=0.002), indicating linkage between CRP and TRL metabolism.
CONCLUSION: The main determinant of plasma CRP levels was CRP production rate. Moreover a significant linkage between CRP metabolism and both TRL apoB-100 and apoB-48 catabolism was noted.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23018145      PMCID: PMC4315144          DOI: 10.1016/j.metabol.2012.08.008

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  35 in total

1.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

Review 2.  C-reactive protein: a critical update.

Authors:  Mark B Pepys; Gideon M Hirschfield
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

3.  Elevated C-reactive protein levels in overweight and obese adults.

Authors:  M Visser; L M Bouter; G M McQuillan; M H Wener; T B Harris
Journal:  JAMA       Date:  1999-12-08       Impact factor: 56.272

4.  Weight loss reduces C-reactive protein levels in obese postmenopausal women.

Authors:  André Tchernof; Amy Nolan; Cynthia K Sites; Philip A Ades; Eric T Poehlman
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

5.  Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity.

Authors:  Bettina Mittendorfer; Bruce W Patterson; Samuel Klein
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-12-10       Impact factor: 4.310

6.  Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome.

Authors:  Marcelo C Batista; Francine K Welty; Margaret R Diffenderfer; Mark J Sarnak; Ernst J Schaefer; Stefania Lamon-Fava; Bela F Asztalos; Gregory G Dolnikowski; Margaret E Brousseau; Julian B Marsh
Journal:  Metabolism       Date:  2004-10       Impact factor: 8.694

Review 7.  Kinetic studies of lipoprotein metabolism in the metabolic syndrome including effects of nutritional interventions.

Authors:  P Hugh R Barrett; Gerald F Watts
Journal:  Curr Opin Lipidol       Date:  2003-02       Impact factor: 4.776

Review 8.  Obesity and dyslipidemia.

Authors:  Barbara V Howard; Giacomo Ruotolo; David C Robbins
Journal:  Endocrinol Metab Clin North Am       Date:  2003-12       Impact factor: 4.741

9.  Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions.

Authors:  J R McNamara; E J Schaefer
Journal:  Clin Chim Acta       Date:  1987-06-30       Impact factor: 3.786

10.  Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome.

Authors:  Esther M M Ooi; P Hugh R Barrett; Dick C Chan; Paul J Nestel; Gerald F Watts
Journal:  Atherosclerosis       Date:  2007-04-09       Impact factor: 5.162

View more
  4 in total

1.  Practical immunoaffinity-enrichment LC-MS for measuring protein kinetics of low-abundance proteins.

Authors:  Michael E Lassman; Thomas McAvoy; Anita Y H Lee; Derek Chappell; Oitak Wong; Haihong Zhou; Gissette Reyes-Soffer; Henry N Ginsberg; John S Millar; Daniel J Rader; David E Gutstein; Omar Laterza
Journal:  Clin Chem       Date:  2014-04-21       Impact factor: 8.327

2.  Effects of atorvastatin on human C-reactive protein metabolism.

Authors:  Nuntakorn Thongtang; Margaret R Diffenderfer; Esther M M Ooi; Bela F Asztalos; Gregory G Dolnikowski; Stefania Lamon-Fava; Ernst J Schaefer
Journal:  Atherosclerosis       Date:  2012-11-23       Impact factor: 5.162

3.  Assessment of the Effect of Selenium Supplementation on Production of Selected Cytokines in Women with Hashimoto's Thyroiditis.

Authors:  Jadwiga Kryczyk-Kozioł; Ewelina Prochownik; Anna Błażewska-Gruszczyk; Marian Słowiaczek; Qian Sun; Lutz Schomburg; Ewa Ochab; Mirosław Bartyzel; Paweł Zagrodzki
Journal:  Nutrients       Date:  2022-07-13       Impact factor: 6.706

4.  Genetically Determined Chronic Low-Grade Inflammation and Hundreds of Health Outcomes in the UK Biobank and the FinnGen Population: A Phenome-Wide Mendelian Randomization Study.

Authors:  Shucheng Si; Jiqing Li; Marlvin Anemey Tewara; Fuzhong Xue
Journal:  Front Immunol       Date:  2021-07-27       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.